143 related articles for article (PubMed ID: 26004093)
1. Nitrergic system and plasmatic methylarginines: Evidence of their role in the perinatal programming of cardiovascular diseases.
Bassareo PP; Mussap M; Bassareo V; Flore G; Mercuro G
Clin Chim Acta; 2015 Dec; 451(Pt A):21-7. PubMed ID: 26004093
[TBL] [Abstract][Full Text] [Related]
2. Intraplatelet L-Arginine-Nitric Oxide Metabolic Pathway: From Discovery to Clinical Implications in Prevention and Treatment of Cardiovascular Disorders.
Gawrys J; Gajecki D; Szahidewicz-Krupska E; Doroszko A
Oxid Med Cell Longev; 2020; 2020():1015908. PubMed ID: 32215167
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Böger RH
Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
[TBL] [Abstract][Full Text] [Related]
4. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
5. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
Böger RH; Ron ES
Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide bioavailability dysfunction involves in atherosclerosis.
Chen JY; Ye ZX; Wang XF; Chang J; Yang MW; Zhong HH; Hong FF; Yang SL
Biomed Pharmacother; 2018 Jan; 97():423-428. PubMed ID: 29091892
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Vallance P; Leiper J
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.
Böger RH; Maas R; Schulze F; Schwedhelm E
Clin Chem Lab Med; 2005; 43(10):1124-9. PubMed ID: 16197309
[TBL] [Abstract][Full Text] [Related]
10. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
11. [The importance of regulation of endogenous methylarginine concentrations in clinical practice].
Kopieczna-Grzebieniak E; Goss M
Przegl Lek; 2005; 62(12):1494-501. PubMed ID: 16786781
[TBL] [Abstract][Full Text] [Related]
12. The pivotal role of nitric oxide for vascular health.
Cooke JP
Can J Cardiol; 2004 Aug; 20 Suppl B():7B-15B. PubMed ID: 15309199
[TBL] [Abstract][Full Text] [Related]
13. [Asymmetric dimethylarginine: predictor of cardiovascular diseases?].
Németh B; Kustán P; Németh Á; Lenkey Z; Cziráki A; Kiss I; Sulyok E; Ajtay Z
Orv Hetil; 2016 Mar; 157(13):483-7. PubMed ID: 26996894
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, NO and collateral growth.
Kocaman SA
Anadolu Kardiyol Derg; 2009 Oct; 9(5):417-20. PubMed ID: 19819795
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
17. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
Caplin B; Leiper J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1343-53. PubMed ID: 22460557
[TBL] [Abstract][Full Text] [Related]
18. Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease.
Papageorgiou N; Androulakis E; Papaioannou S; Antoniades C; Tousoulis D
Amino Acids; 2015 Sep; 47(9):1741-50. PubMed ID: 26123985
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
Chan NN; Chan JC
Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition.
Bermúdez V; Bermúdez F; Acosta G; Acosta A; Añez J; Andara C; Leal E; Cano C; Manuel V; Hernández R; Israili Z
Am J Ther; 2008; 15(4):326-33. PubMed ID: 18645335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
